Shopping Cart 0
Cart Subtotal
USD 0

Laboratorios Del Dr Esteve SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Laboratorios Del Dr Esteve SA (Esteve) researches, develops and markets prescription and generic pharmaceutical products. The company's product portfolio encompasses innovative prescription drugs, over-the-counter (OTC) pharmaceuticals and generic drugs. It offers drugs in central nervous system, infection, respiratory, cardiovascular, cancer, primary care and other therapeutic areas. Esteve also develops, manufactures and markets active pharmaceutical ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. The company markets its products to pharmaceutical companies, healthcare facilities, and other customers through licensing agreements and distributors. It operates subsidiaries and production centers in Europe, America and Asia. Esteve is headquartered in Barcelona, Spain.

Laboratorios Del Dr Esteve SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Breckenridge Pharma Acquires Five ANDA's from Nostrum Lab 12

Breckenridge Pharma Acquires ANDA from Impopharma 13

Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For USUSD30 Million 14

Partnerships 16

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 16

Breckenridge Pharma Enters into Agreement with Sam Chun Dang Pharm 17

Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 18

Esteve Enters into Agreement with AstraZeneca 19

Eisai Enters into Agreement with Esteve 20

Enzymatica Enters into Distribution Agreement with Esteve 21

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 22

Breckenridge Pharma Enters into Co-Marketing Agreement with MSN Labs for ANDAs 23

Breckenridge Pharma Enters into Co-Development Agreement with Pharmaceutics International 24

SEFAC and Esteve Forms partnership 25

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 26

Breckenridge Pharma Enters Into Co-Development Agreement With Welding And SK Chemicals 27

Breckenridge Pharma Enters Into Co-Marketing Agreement With Aptalis Pharmatech For Inderal LA 28

Breckenridge Pharma Enters Into Co-Marketing Agreement With Marksans Pharma For Gabapentin Capsules 29

Breckenridge Pharma Enters Into Co-Marketing Agreement With Ajanta Pharma For Risperdal Tablet 30

Pamlab Enters Into Joint Venture With Breckenridge To Distribute Medical Food Products 31

Breckenridge Pharma Enters Into Co-Marketing Agreement With Zhejiang Huahai Pharma For Nevirapine 32

Licensing Agreements 33

ReGenX Biosciences Enters Into Licensing Agreement With Esteve 33

Asset Transactions 34

Ecuphar Acquires Veterinary Division from Esteve 34

Laboratorios Del Dr Esteve SA-Key Competitors 35

Laboratorios Del Dr Esteve SA-Key Employees 36

Laboratorios Del Dr Esteve SA-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Joint Venture 39

Recent Developments 40

Government and Public Interest 40

Oct 23, 2017: Researchers prove the effectiveness of a new drug to prevent the onset and the pain of chemotherapy-induced neuropathy 40

Other Significant Developments 41

Mar 19, 2018: Pensa Pharma Renews its Corporate Website and Launches Local Websites 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Laboratorios Del Dr Esteve SA, Deals By Therapy Area, 2012 to YTD 2018 9

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Breckenridge Pharma Acquires Five ANDA's from Nostrum Lab 12

Breckenridge Pharma Acquires ANDA from Impopharma 13

Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For USUSD30 Million 14

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 16

Breckenridge Pharma Enters into Agreement with Sam Chun Dang Pharm 17

Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 18

Esteve Enters into Agreement with AstraZeneca 19

Eisai Enters into Agreement with Esteve 20

Enzymatica Enters into Distribution Agreement with Esteve 21

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 22

Breckenridge Pharma Enters into Co-Marketing Agreement with MSN Labs for ANDAs 23

Breckenridge Pharma Enters into Co-Development Agreement with Pharmaceutics International 24

SEFAC and Esteve Forms partnership 25

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 26

Breckenridge Pharma Enters Into Co-Development Agreement With Welding And SK Chemicals 27

Breckenridge Pharma Enters Into Co-Marketing Agreement With Aptalis Pharmatech For Inderal LA 28

Breckenridge Pharma Enters Into Co-Marketing Agreement With Marksans Pharma For Gabapentin Capsules 29

Breckenridge Pharma Enters Into Co-Marketing Agreement With Ajanta Pharma For Risperdal Tablet 30

Pamlab Enters Into Joint Venture With Breckenridge To Distribute Medical Food Products 31

Breckenridge Pharma Enters Into Co-Marketing Agreement With Zhejiang Huahai Pharma For Nevirapine 32

ReGenX Biosciences Enters Into Licensing Agreement With Esteve 33

Ecuphar Acquires Veterinary Division from Esteve 34

Laboratorios Del Dr Esteve SA, Key Competitors 35

Laboratorios Del Dr Esteve SA, Key Employees 36

Laboratorios Del Dr Esteve SA, Other Locations 37

Laboratorios Del Dr Esteve SA, Subsidiaries 37

Laboratorios Del Dr Esteve SA, Joint Venture 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Laboratorios Del Dr Esteve SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Laboratorios Del Dr Esteve SA (Esteve) researches, develops and markets prescription and generic pharmaceutical products. The company's product portfolio encompasses innovative prescription drugs, over-the-counter (OTC) pharmaceuticals and generic drugs. It offers drugs in central nervous system, infection, respiratory, cardiovascular, cancer, primary care and other therapeutic areas. Esteve also develops, manufactures and markets active pharmaceutical ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. The company markets its products to pharmaceutical companies, healthcare facilities, and other customers through licensing agreements and distributors. It operates subsidiaries and production centers in Europe, America and Asia. Esteve is headquartered in Barcelona, Spain.

Laboratorios Del Dr Esteve SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Breckenridge Pharma Acquires Five ANDA's from Nostrum Lab 12

Breckenridge Pharma Acquires ANDA from Impopharma 13

Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For USUSD30 Million 14

Partnerships 16

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 16

Breckenridge Pharma Enters into Agreement with Sam Chun Dang Pharm 17

Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 18

Esteve Enters into Agreement with AstraZeneca 19

Eisai Enters into Agreement with Esteve 20

Enzymatica Enters into Distribution Agreement with Esteve 21

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 22

Breckenridge Pharma Enters into Co-Marketing Agreement with MSN Labs for ANDAs 23

Breckenridge Pharma Enters into Co-Development Agreement with Pharmaceutics International 24

SEFAC and Esteve Forms partnership 25

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 26

Breckenridge Pharma Enters Into Co-Development Agreement With Welding And SK Chemicals 27

Breckenridge Pharma Enters Into Co-Marketing Agreement With Aptalis Pharmatech For Inderal LA 28

Breckenridge Pharma Enters Into Co-Marketing Agreement With Marksans Pharma For Gabapentin Capsules 29

Breckenridge Pharma Enters Into Co-Marketing Agreement With Ajanta Pharma For Risperdal Tablet 30

Pamlab Enters Into Joint Venture With Breckenridge To Distribute Medical Food Products 31

Breckenridge Pharma Enters Into Co-Marketing Agreement With Zhejiang Huahai Pharma For Nevirapine 32

Licensing Agreements 33

ReGenX Biosciences Enters Into Licensing Agreement With Esteve 33

Asset Transactions 34

Ecuphar Acquires Veterinary Division from Esteve 34

Laboratorios Del Dr Esteve SA-Key Competitors 35

Laboratorios Del Dr Esteve SA-Key Employees 36

Laboratorios Del Dr Esteve SA-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Joint Venture 39

Recent Developments 40

Government and Public Interest 40

Oct 23, 2017: Researchers prove the effectiveness of a new drug to prevent the onset and the pain of chemotherapy-induced neuropathy 40

Other Significant Developments 41

Mar 19, 2018: Pensa Pharma Renews its Corporate Website and Launches Local Websites 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Laboratorios Del Dr Esteve SA, Deals By Therapy Area, 2012 to YTD 2018 9

Laboratorios Del Dr Esteve SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Breckenridge Pharma Acquires Five ANDA's from Nostrum Lab 12

Breckenridge Pharma Acquires ANDA from Impopharma 13

Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For USUSD30 Million 14

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 16

Breckenridge Pharma Enters into Agreement with Sam Chun Dang Pharm 17

Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 18

Esteve Enters into Agreement with AstraZeneca 19

Eisai Enters into Agreement with Esteve 20

Enzymatica Enters into Distribution Agreement with Esteve 21

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 22

Breckenridge Pharma Enters into Co-Marketing Agreement with MSN Labs for ANDAs 23

Breckenridge Pharma Enters into Co-Development Agreement with Pharmaceutics International 24

SEFAC and Esteve Forms partnership 25

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 26

Breckenridge Pharma Enters Into Co-Development Agreement With Welding And SK Chemicals 27

Breckenridge Pharma Enters Into Co-Marketing Agreement With Aptalis Pharmatech For Inderal LA 28

Breckenridge Pharma Enters Into Co-Marketing Agreement With Marksans Pharma For Gabapentin Capsules 29

Breckenridge Pharma Enters Into Co-Marketing Agreement With Ajanta Pharma For Risperdal Tablet 30

Pamlab Enters Into Joint Venture With Breckenridge To Distribute Medical Food Products 31

Breckenridge Pharma Enters Into Co-Marketing Agreement With Zhejiang Huahai Pharma For Nevirapine 32

ReGenX Biosciences Enters Into Licensing Agreement With Esteve 33

Ecuphar Acquires Veterinary Division from Esteve 34

Laboratorios Del Dr Esteve SA, Key Competitors 35

Laboratorios Del Dr Esteve SA, Key Employees 36

Laboratorios Del Dr Esteve SA, Other Locations 37

Laboratorios Del Dr Esteve SA, Subsidiaries 37

Laboratorios Del Dr Esteve SA, Joint Venture 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Laboratorios Del Dr Esteve SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.